In Japan, the research and development (R&D) process of a new drug, from synthesizing new compounds to supplying the drug in the market, is largely affected by the legal regulations under the Pharmaceutical Affairs Law and the drug price standards under the Health Insurance Law. In recent years, the "hollowing-out" of new drug R&D has been observed in Japan, which involves a decrease in new drug development, the lengthening of development periods, and the shifting of development to overseas. This article presents an international comparison and analysis from an economic standpoint on how Japan's regulations affect new drug R&D. The results of the analysis indicate that establishing the infrastructure for clinical trials and drug reviews, improving the efficiency of and adding incentives to clinical trials, and pricing new drugs appropriately relative to generic drugs are necessary conditions for promoting new drug R&D in Japan.
Download Info
To download:
If you experience problems downloading a file, check if you have the
proper application to
view it first. Information about this may be contained
in the File-Format links below. In case of further problems read
the IDEAS help
page. Note that these files are not on the IDEAS
site. Please be patient as the files may be large.
As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.
Publisher Info
Article provided by M.E. Sharpe, Inc. in its journal Japanese Economy.
Volume (Year): 35 (2008) Issue (Month): 4 (December) Pages: 107-132 Download reference. The following formats are available: HTML
(with abstract),
plain text
(with abstract),
BibTeX,
RIS (EndNote, RefMan, ProCite),
ReDIF